Available Technological Offer
A family of quinolyl nitrone derivatives has been identified as potential agents for the prevention or treatment of hearing loss caused by physical factors, such as noise or exposure to ototoxic substances.
Novel glycolipid mimetics able to express anti-inflammatory or adjuvant activity in a context dependent manner. The compounds can be used for the treatment of immune diseases cursed with Th1/Th2 imbalance or as vaccine adjuvants.
Compounds and its use for the treatment of diseases caused by RNA viruses, such as West Nile virus (WNV), Zika virus (ZIKV), among others.
New family of molecules derived from Isoquercetin for the treatment and/or prevention of inflammatory and degenerative eye diseases.
Design of a novel proteolytic set of chimeras (26STACs) directed at the degradation of the ceramide transfer protein CERT-1 by the proteasome, in an E3-independent manner, for its use in the treatment of breast cancer.
Novel antiviral strategy targeting viral non-essential proteins (NEPs), scarcely prone to adaptive mutations. As a proof of concept, SARS-CoV-2 ORF9b homodimerization inhibitors have been identified that prevents the virus hyperinflammation response.
Andrographolide derivatives for its use as treatment for inflammatory diseases related to cytokine storm.
New family of molecules with potent and selective antiviral activity in cellular models of infection by various coronaviruses such as SARS-CoV-2, MERS-CoV, hCoV-229E. They do not show cytotoxicity or activity against other viruses with RNA genome such as West Nile fever virus, dengue virus and vesicular stomatitis virus at relevant doses.
Novel small molecules as valuable agents for controlling bleeding after heparin treatment. Lead compound studied has shown high efficacy and is expected to overcome side effects produced by current antidotes used in clinics.